AbCellera Biologics (ABCL) to Post Quarterly Earnings on Wednesday

AbCellera Biologics (NASDAQ:ABCL) will likely be releasing its Q2 2026 results after the market closes on Wednesday, August 5th. Analysts expect the company to post earnings of ($0.1443) per share and revenue of $7.8480 million for the quarter. Individuals can find conference call details on the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Wednesday, August 5, 2026 at 5:00 PM ET.

AbCellera Biologics (NASDAQ:ABCL) last released its quarterly earnings data on Monday, May 11th. The company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.22) by $0.08. The firm had revenue of $8.31 million for the quarter, compared to the consensus estimate of $5.41 million. AbCellera Biologics had a negative net margin of 181.75% and a negative return on equity of 14.86%. During the same period in the previous year, the company earned ($0.15) earnings per share. On average, analysts expect AbCellera Biologics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

AbCellera Biologics Price Performance

Shares of ABCL opened at $5.83 on Tuesday. The company’s 50-day moving average is $6.17 and its 200-day moving average is $4.63. The firm has a market capitalization of $1.78 billion, a PE ratio of -12.15 and a beta of 1.20. AbCellera Biologics has a fifty-two week low of $2.74 and a fifty-two week high of $8.44.

Institutional Trading of AbCellera Biologics

A number of institutional investors have recently bought and sold shares of the business. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new position in shares of AbCellera Biologics during the fourth quarter worth $26,938,000. Two Sigma Investments LP boosted its holdings in shares of AbCellera Biologics by 25.9% during the 3rd quarter. Two Sigma Investments LP now owns 5,175,142 shares of the company’s stock valued at $26,031,000 after acquiring an additional 1,064,290 shares in the last quarter. Goldman Sachs Group Inc. grew its position in AbCellera Biologics by 1,636.3% during the 4th quarter. Goldman Sachs Group Inc. now owns 4,344,485 shares of the company’s stock worth $14,858,000 after acquiring an additional 4,094,268 shares during the last quarter. Bank of America Corp DE increased its holdings in AbCellera Biologics by 977.8% in the 3rd quarter. Bank of America Corp DE now owns 2,418,304 shares of the company’s stock worth $12,164,000 after purchasing an additional 2,193,939 shares in the last quarter. Finally, Tudor Investment Corp ET AL increased its holdings in AbCellera Biologics by 146.0% in the 4th quarter. Tudor Investment Corp ET AL now owns 1,796,010 shares of the company’s stock worth $6,142,000 after purchasing an additional 1,065,888 shares in the last quarter. Institutional investors own 61.42% of the company’s stock.

Analyst Ratings Changes

A number of research analysts recently commented on ABCL shares. Wall Street Zen lowered shares of AbCellera Biologics from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Weiss Ratings restated a “sell (d-)” rating on shares of AbCellera Biologics in a report on Friday, July 17th. Cantor Fitzgerald initiated coverage on AbCellera Biologics in a research report on Tuesday, May 5th. They issued an “overweight” rating and a $7.00 target price on the stock. JonesTrading began coverage on AbCellera Biologics in a report on Friday, April 10th. They set a “buy” rating and a $11.00 price target for the company. Finally, Benchmark upgraded AbCellera Biologics from a “hold” rating to a “buy” rating and set a $11.00 price target for the company in a research note on Tuesday, July 7th. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, AbCellera Biologics has an average rating of “Moderate Buy” and an average target price of $8.00.

AbCellera Biologics Company Profile

AbCellera Biologics Inc (NASDAQ: ABCL) is a biotechnology company specializing in the discovery and development of therapeutic antibodies. The company’s technology platform integrates single-cell screening, microfluidics, high-throughput sequencing and artificial intelligence to rapidly identify and optimize antibody candidates against a wide range of disease targets. By combining experimental data with machine learning, AbCellera accelerates early-stage drug discovery and improves the efficiency of lead candidate selection.

AbCellera primarily operates through partnerships with pharmaceutical and biotechnology firms, offering its antibody discovery services on a fee-for-service and milestone-driven basis.